Danube Pharmaceuticals Inc.
This article was originally published in Start Up
Executive SummaryBiotech start-up Danube Pharmaceuticals Inc. has in-licensed what it calls the only dual-mechanism of action, orally available small molecule in clinical testing for glaucoma, a leading cause of irreversible blindness worldwide.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.